Price
No data yet.
Social Signal Score
Analyst Ratings
9 analystsRevenue
$2.29MAnalyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Mahesh V. Patel
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 14
- Beta
- 0.50
- Country
- US
- Piotroski score
- 1 / 9 (Weak)
- Altman Z-score
- -8.30
Financials
Revenue
$2.29M+435.0%Net Income
$-666.2KEBITDA
$-666.2KFree Cash Flow
$-1.81MEPS (diluted)
$-0.08Shares Outstanding (diluted)
8.24M+666.9%Operating Expenses
$3.16MCash & Debt
$21.46MReturn of Capital
$0.00Revenue by Segment (annual)
$298.1KQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $1.98M | $-9.63M | $-1.77 |
| 2024 | $11.20M | $8.4K | $0.00 |
| 2023 | $-2.85M | $-16.35M | $-3.14 |
| 2022 | $500.0K | $-10.76M | $-2.15 |
| 2021 | $16.14M | $-634.4K | $-0.19 |
| 2020 | $0.00 | $-20.96M | $-6.46 |
| 2019 | $165.0K | $-13.01M | $-8.54 |
| 2018 | $428.0K | $-11.66M | $-9.35 |
| 2017 | $0.00 | $-20.98M | $-17.79 |
| 2016 | $0.00 | $-18.97M | $-17.66 |
| 2015 | $0.00 | $-18.21M | $-18.79 |
| 2014 | $0.00 | $-20.37M | $-27.13 |
| 2013 | $0.00 | $-10.59M | $-24.45 |
| 2012 | $7.71M | $3.80M | $14.45 |
Valuation
LPCNhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
100+0.00%Social Signal Score
Mentions (5)
- Newsprnewswire.com·17d ago·Neutral
Lipocine Announces Financial Results for the Third Quarter of 2026 SALT LAKE CITY, Nov. 5, 2026 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a specialty pharmaceutical company focused on the development of novel oral therapeutics, today announced financial results for the third quarter ended September 30, 2026 and provided a corporate update. Recent Developments and Corporate Update LPCN 1154 (BRLIZIO™) for Postpartum Depression (PPD) In September 2026, Lipocine announced the initiation of the …
View source ↗ - Newszacks.com·45d ago·Neutral
Here's Why You Should Add LPCN Stock to Your Portfolio Now Lipocine's Tlando royalties, Brlizio's phase III trial and broader pipeline offer multiple potential growth drivers and catalysts.
View source ↗ - Newsprnewswire.com·46d ago·Neutral
Lipocine Announces Health Canada Approval of TLANDO® for Testosterone Replacement Therapy SALT LAKE CITY, Oct. 7, 2026 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a specialty pharmaceutical company focused on the development of novel oral therapeutics, today announced that, through Lipocine's licensing partner Verity Pharmaceuticals Inc (Verity Pharma), Health Canada has approved TLANDO® (testosterone undecanoate) capsules for testosterone replacement therapy in adult males for the conditions …
View source ↗ - Newszacks.com·60d ago·Positive
Lipocine (LPCN) Upgraded to Buy: What Does It Mean for the Stock? Lipocine (LPCN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
View source ↗ - Newsprnewswire.com·69d ago·Neutral
Lipocine Announces Initiation of BLOOM Phase 3 Study of LPCN 1154 for Postpartum Depression Study informed by encouraging exploratory efficacy findings and a favorable safety profile in the prior Phase 3 trial Approximately 120 participants with severe postpartum depression (PPD) planned; first participant dosing expected in early Q4 2026 Company expects existing resources to support BLOOM SALT LAKE CITY, Sept. 14, 2026 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a specialty pharmaceutical com…
View source ↗
Earnings
Mon, Mar 8(in 4 months)
Consensus estimate $-0.33 per share
Typical surprise +0.0% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Nov 5$-0.08 vs $-0.39beat
- Tue, Aug 4$-0.32 vs $-0.40beat
- Thu, May 7$-0.54 vs $-0.51miss
- Mon, Mar 9$-0.34 vs $-0.60beat
- Thu, Nov 6$-0.59 vs $-0.56miss
- Tue, Aug 5$-0.41 vs $-0.41beat
Estimates and results for LPCN via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by LPCN officers and directors.
- Bought
- $1.1m
- Sold
- $109k
21 trades
5 trades
- Higuchi John W.bought
- Higuchi John W.bought
- Patel Mahesh V.bought
- Patel Mahesh V.bought
- Higuchi John W.bought
- Higuchi John W.bought
- Higuchi John W.bought
- Higuchi John W.bought
74 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in LPCN.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
